James Ryan (@JRyan_1981) header
James Ryan (@JRyan_1981) profile picture

#1 open label hater | Opinions are my own

Joined February 2026
Photo by James Ryan (@JRyan_1981)Photo by James Ryan (@JRyan_1981)Photo by James Ryan (@JRyan_1981)Photo by James Ryan (@JRyan_1981)Photo by James Ryan (@JRyan_1981)Photo by James Ryan (@JRyan_1981)Photo by James Ryan (@JRyan_1981)Photo by James Ryan (@JRyan_1981)Photo by James Ryan (@JRyan_1981)Photo by James Ryan (@JRyan_1981)
Replying to @Capricor
4
230
FDA statement on $CAPR is nearly unprecedented. We must send the message via the @USDOJ, which I am absolutely loathe to recommend on anyone for obvious reasons, that manipulating clinical trial data is the worst possible crime in biotech and life sciences. cc @linda_marban @AGToddBlanche
34
36
6
536
95,102
me: "please summarize and evaluate the claims made in this short report" Claude: "read one page. deciding whether or not to read the rest of the report." AI is getting a little too human-like
7
5
79
5,339
$ABVX so Scorpion argue that obe accumulates more in fat, but they also say it's 1 million times more distributive in water than octanol (slide 69) I'm starting to think these guys don't know what they're talking about...
1
21
843
$ABVX love the idea that drugs can't be repurposed
1
275
$ABVX just another generational opportunity. That report is a load of total, utter crap lmao
1
296
James Ryan retweeted
I guess this is what happens when you have the worst retail investors of all time
1
1
7
1,068
Given $SVRA FDA communication and $BLTE FDA communication, surely $CAPR has the verdict with them right now?
488
$INSM one of the best drug launches of all time, very interesting pipeline, great management team Company could go far on their own ($REGN, $VRTX, $ARGX etc.) but great opportunity for $SNY to bring into the fold and get some momentum behind them
1
2
376
$SLS “positive data” in the same way $CAPR had positive data
4
6
2,938
James Ryan retweeted
$ARWR RBC PT 💯 notes no read through from the $IONS slow start and reiterated $3-4b peak sales potential. Initial focus will be in the high-risk population (TG≥880 without AP history and ≥500 with AP history) as ARWR notes 9 patients needed to treat to prevent one AP at one year among those at high risk and only 3 for the latter subgroup. On the pipeline, ALK7/INHBE data is on track for YE-26 (obese non-diabetic monotherapy and GLP-1 combo in obese with T2D), HoFH will read out pivotal in mid-27, PCSK9/APOC3 dimer update is mid-27 (regulatory approach revolves around LDL lowering)
1
1
1
17
7,257
If you’ve never heard this, enjoy.. 😂🤣
Happy Taylor Wimpey earnings day folks…
1
140
“The U.S. Food and Drug Administration (FDA) recommended that Hemab consider a randomized controlled design. However, the FDA acknowledged Hemab’s concerns about the feasibility of randomization in GT”
37
Among patients with hypertension due to primary aldosteronism, reductions in blood pressure and the aldosterone-to-renin ratio persisted for 2 years after completion of an extended course of aldosterone synthase inhibition. Full study results: nej.md/4jXjULO #ScientificSessions26 | @AHAScience
2
172
FDA has gone totally the other way in approving everything recently. It’s incredibly important not to let non-efficacious, dangerous products onto the market under the guise of ‘unmet patient need’ Mainly $CAPR ⬇️ but also $QURE which is yet to demonstrate any meaningful benefit
$CAPR I am more convinced than ever the FDA is going to reject deramiocel at the end of the month. Why? Because if all was going well with the review, and Capricor was confident the FDA was going to approve its cell therapy, Dr. Craig McDonald would not have publicly posted this letter submitted to the FDA — one month before the PDUFA date. lnkd.in/p/gCCH65Mk The only reason McDonald made this letter public was because Capricor knows its application is in trouble, therefore it is trying to apply more public pressure to get the FDA to change its mind.
5
4
2,013